In combination with fulvestrant for patients with HR+/HER2− aBC or mBC with PIK3CA, AKT1, or PTEN alterations following progression on or after ET ± CDK4/6i
Learn more about upcoming changes to Medicare Part D in 2025
Access 360
Helping patients access the care they need
The AstraZeneca Access 360TM program provides personal support to help streamline access and reimbursement for TRUQAP.
Access 360 provides:
- Assistance with understanding patient insurance coverage and pharmacy options
- Prior authorization support
- Claims and appeal process support
- Eligibility requirements and enrollment assistance with AstraZeneca’s Patient Savings Programs
- Referrals to AZ&MeTM Prescription Savings Program, AstraZeneca’s patient assistance program
- Information about independent charitable patient assistance foundations
To learn more about the
AstraZeneca Access 360TM program, please call
1-844-ASK-A360 (1-844-275-2360), Monday through Friday, 8 AM - 6 PM ET or visit www.MyAccess360.com.
How to Enroll Your Patients in Access 360
To get your patients started, choose the most convenient method of enrollment:
Download the enrollment form, complete and fax to 1-833-FAX-A360 (1-833-329-2360)
Call Access 360 at 1-844-275-2360 Monday to Friday, 8 AM – 6 PM ET
Visit the provider portal at ProviderPortal.MyAccess360.com
For Access 360 to best support your patient, a Patient Authorization Form (PAF) is required. The PAF can be completed either on page 2 of the Enrollment Form or online with the Electronic Patient Authorization Form (ePAF).
TRUQAP Patient Savings Program
The TRUQAP Patient Savings Program can help eligible commercially insured patients with their out-of-pocket costs
PATIENTS MAY PAY AS LITTLE AS
PATIENTS MAY PAY AS LITTLE AS
PER MONTH
- Patients may pay as little as $0 per month for TRUQAP. There are no income requirements to participate in the program
- You can help enroll your patients in the program and file claims on their behalf. For more information and eligibility requirements, visit www.azpatientsupport.com or call AstraZeneca Access 360TM at 1-844-ASK-A360 (1-844-275-2360)*
PER MONTH
Resources
The following resources are available for download.
Gain an expert’s perspective on treatment with TRUQAP + fulvestrant
Dr Iyengar Video
Video
Acquisition Information
Connect with select Specialty Pharmacy Partners (SPPs) and Specialty Distributors. These SPPs also provide support to help patients with their prescribed treatments:
Specialty Pharmacy Providers
BIOLOGICS BY MCKESSON
p: 1-800-850-4306
f: 1-800-823-4506
biologicsinc.com
ONCO360 ONCOLOGY PHARMACY
p: 1-877-662-6633
f: 1-877-662-6355
www.onco360.com
Specialty Distributors
AMERISOURCEBERGEN
ASD Healthcare
p: 1-800-746-6273
f: 1-800-547-9413
asdhealthcare.com
Oncology Supply
p: 1-800-633-7555
f: 1-800-248-8205
oncologysupply.com
BIOCARESD
p: 1-800-304-3064
f: 1-602-840-6215
biocare-us.com
CARDINAL HEALTH SPECIALTY DISTRIBUTION
p: 1-855-740-1871
f: 1-888-345-4916
specialtyonline.cardinalhealth.com
CURASCRIPT SD
p: 1-877-599-7748
f: 1-800-862-6208
curascriptsd.com
DAKOTA DRUG, INC.
p: 1-866-210-5887
f: 1-763-421-0661
dakdrug.com
DMS PHARMACEUTICAL
p: 1-877-788-1100
f: 1-847-518-1105
dmspharma.com
MCKESSON SPECIALTY
McKesson Specialty Health (MD Offices)
p: 1-800-482-6700
f: 1-800-289-9285
mscs.mckesson.com
McKesson Plasma and Biologics (Hospitals, IDNs, VA)
p: 1-877-625-2566
f: 1-888-752-7626
mckesson.com/plasmabiologics
See the optimized
schedule
Dive into the data
IMPORTANT SAFETY INFORMATION ABOUT TRUQAP® (capivasertib) tablets
TRUQAP is contraindicated in patients with severe hypersensitivity to TRUQAP or any of its components.
Hyperglycemia
Severe hyperglycemia, including diabetic ketoacidosis and fatal outcomes, can occur in patients treated with TRUQAP (n=355).
Increased fasting glucose (FG) from baseline occurred in 37% of patients treated with TRUQAP, including 11% of patients with Grade 2 (FG >160 to 250 mg/dL), 2% with Grade 3 (FG >250 to 500 mg/dL), and 1.1% with Grade 4 (FG >500 mg/dL) events. The median time to first occurrence of hyperglycemia was 15 days (range: 1 to 367). Dose reduction for hyperglycemia was required in 0.6% of patients and permanent discontinuation was required in 0.6% of patients. Diabetic ketoacidosis occurred in 0.3% of patients and diabetic metabolic decompensation in 0.6% of patients.
In CAPItello-291, 12% (43/355) of patients who received TRUQAP had an anti-hyperglycemic medication either initiated or changed during the study, including treatment with insulin in 4.8% (17/355) of patients.
The safety of TRUQAP has not been established in patients with Type I diabetes or diabetes requiring insulin. Patients with insulin-dependent diabetes were excluded from CAPItello-291.
Before initiating treatment with TRUQAP, test fasting glucose levels (fasting plasma glucose or fasting blood glucose), hemoglobin A1C (HbA1C) levels, and optimize fasting glucose. After initiating treatment with TRUQAP, monitor or self-monitor FG levels on Day 3 or 4 of the dosing week during weeks 1, 2, 4, 6, and 8; then monthly while on treatment with TRUQAP; and as clinically indicated. Monitor HbA1C levels every 3 months during treatment with TRUQAP and as clinically indicated. Patients with a history of well-controlled Type 2 diabetes mellitus may require intensified anti-hyperglycemic treatment and close monitoring of FG levels.
For patients who experience hyperglycemia during treatment with TRUQAP, monitor FG at least twice weekly, on days on and off TRUQAP, until FG decreases to baseline levels. During treatment with anti-diabetic medications, monitor FG at least once a week for 2 months, followed by once every 2 weeks, or as clinically indicated. Consider consultation with a healthcare practitioner with expertise in the treatment of hyperglycemia and initiation of FG monitoring at home for patients who have risk factors for hyperglycemia or who experience hyperglycemia. Advise patients on the signs and symptoms of hyperglycemia and counsel patients on lifestyle changes.
Withhold TRUQAP immediately when ketoacidosis is suspected. If ketoacidosis is confirmed, permanently discontinue TRUQAP. Based on the severity of hyperglycemia, withhold, reduce dose, or permanently discontinue TRUQAP.
Diarrhea
Severe diarrhea associated with dehydration occurred in patients who received TRUQAP (n=355).
Diarrhea occurred in 72% of patients. Grade 3 or 4 diarrhea occurred in 9% of patients. The median time to first occurrence was 8 days (range: 1 to 519). In the 257 patients with diarrhea, 59% required antidiarrheal medications to manage symptoms. Dose reductions were required in 8% of patients and 2% of patients permanently discontinued TRUQAP due to diarrhea. In patients with Grade ≥2 diarrhea (n=93) with at least 1 grade improvement (n=89), median time to improvement from the first event was 4 days (range: 1 to 154).
Monitor patients for signs and symptoms of diarrhea. Advise patients to increase oral fluids and start antidiarrheal treatment at the first sign of diarrhea while taking TRUQAP. Withhold, reduce dose, or permanently discontinue TRUQAP based on severity.
Cutaneous Adverse Reactions
Cutaneous adverse reactions, which can be severe, including erythema multiforme (EM), palmar-plantar erythrodysesthesia, and drug reaction with eosinophilia and systemic symptoms (DRESS), occurred in patients who received TRUQAP (n=355).
Cutaneous adverse reactions occurred in 58% of patients. Grade 3 or 4 cutaneous adverse reactions occurred in 17% of patients receiving TRUQAP. EM occurred in 1.7% of patients and DRESS occurred in 0.3% of patients. Dose reduction was required in 7% of patients and 7% of patients permanently discontinued TRUQAP due to cutaneous adverse reactions.
Monitor patients for signs and symptoms of cutaneous adverse reactions. Early consultation with a dermatologist is recommended. Withhold, dose reduce, or permanently discontinue TRUQAP based on severity.
Embryo-Fetal Toxicity
Based on findings from animals and mechanism of action, TRUQAP can cause fetal harm when administered to a pregnant woman. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TRUQAP and for 1 month after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with TRUQAP and for 4 months after the last dose.
TRUQAP is used in combination with fulvestrant. Refer to the full Prescribing Information of fulvestrant for pregnancy and contraception information.
ADVERSE REACTIONS
Among the 355 patients who received TRUQAP in CAPItello-291, the most common (≥20%) adverse reactions, including laboratory abnormalities, were diarrhea (72%), cutaneous adverse reactions (58%), increased random glucose (57%), decreased lymphocytes (47%), decreased hemoglobin (45%), increased fasting glucose (37%), nausea and fatigue (35% each), decreased leukocytes (32%), increased triglycerides (27%), decreased neutrophils (23%), increased creatinine (22%), vomiting (21%), and stomatitis (20%).
In the 155 patients with PIK3CA/AKT1/PTEN alterations treated with TRUQAP + fulvestrant, dose reductions due to adverse reactions were reported in 21% of patients. Permanent TRUQAP discontinuation due to an adverse reaction occurred in 10% of patients. Dose interruptions of TRUQAP occurred in 39% of patients.
DRUG INTERACTIONS
Strong CYP3A Inhibitors: Avoid concomitant use with a strong CYP3A inhibitor. If concomitant use cannot be avoided, reduce the dose of TRUQAP and monitor patients for adverse reactions.
Moderate CYP3A Inhibitors: When concomitantly used with a moderate CYP3A inhibitor, reduce the dose of TRUQAP and monitor patients for adverse reactions.
Strong or Moderate CYP3A Inducers: Avoid concomitant use of TRUQAP with strong or moderate CYP3A inducers.
INDICATION AND USAGE
TRUQAP in combination with fulvestrant is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alteration as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.
You may report side effects related to AstraZeneca products
.
INDICATION AND USAGE
TRUQAP in combination with fulvestrant is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alteration as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.
